New drug combo shows promise against tough head and neck cancers
NCT ID NCT07065630
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called volrustomig combined with standard chemotherapy (paclitaxel and carboplatin) in people with advanced head and neck cancer that is not caused by HPV. The goal is to see if this combination shrinks tumors before further treatment is tailored based on how well the cancer responds. About 38 adults with untreated, locally advanced HPV-negative head and neck cancer will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The University of Chicago
RECRUITINGChicago, Illinois, 60637, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Digital peer support: a new weapon against cancer treatment anxiety?
- Can targeted radiation boost Immunotherapy's power against head and neck cancer?
- Could a simple mouthwash protect cancer patients from Radiation's painful side effects?
- Can tailored nutrition boost recovery from head and neck surgery?
- Can less radiation be safer for throat cancer?
- Can a scan tell who needs more surgery after head and neck cancer?